Supernus Pharmaceuticals
SUPN
57 hedge funds and large institutions have $187M invested in Supernus Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
50% more call options, than puts
Call options by funds: $15.1M | Put options by funds: $10M
47% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 17
10% more capital invested
Capital invested by funds: $170M → $187M (+$16.6M)
8% more funds holding
Funds holding: 53 → 57 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MOACM
Mutual of America Capital Management
New York
|
+$1.07M |
| 2 |
RP
Reinhart Partners
Mequon,
Wisconsin
|
+$1M |
| 3 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$963K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$718K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$672K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$12.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.58M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$637K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$502K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$472K |
SUPN Hedge Fund Activity: Q3 2013 in Review
57 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2013, worth a combined $187M — up 9.7% from $170M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SUPN positions and 5 closed out — a net gain of 4 holders — while 25 added to existing stakes and 17 trimmed.
The largest buyer was Mutual of America Capital Management, adding an estimated $1.07M. The largest seller was OrbiMed, cutting an estimated $12.5M.
- 57 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2013, up from 53 in Q2 2013.
- Funds reported $187M of Supernus Pharmaceuticals stock for Q3 2013, up 9.7% quarter-over-quarter.
- 9 funds opened new Supernus Pharmaceuticals positions in Q3 2013 and 5 closed out, a net change of +4 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2013 was Mutual of America Capital Management, an estimated $1.07M added.
- The largest Supernus Pharmaceuticals seller in Q3 2013 was OrbiMed, an estimated $12.5M sold.
Based on aggregated 13F filings for Q3 2013.